Navigation Links
Indevr launches breakthrough colorimetric detection for microarrays using core technology from CU
Date:11/17/2011

BOULDER, Colo. November 2011 InDevR, a Boulder-based biotechnology company that develops advanced life science instrumentation and assays for analysis of viruses and other microorganisms, announced today the launch revolutionary new technology for microbiological analysis. ampliPHOX, a colorimetric detection system that incorporates core technology licensed from the University of Colorado Technology Transfer Office, will enhance laboratories around the world by offering a cost effective and easy to use alternative to fluorescence detection.

ampliPHOX instrumentation costs less than one-tenth the price of typical fluorescence microarray readers. The ampliPHOX process relies on an innovative photopolymerization approach. Colorimetric readouts with equivalent sensitivity to fluorescence are delivered within minutes and results are visible to the naked eye. ampliPHOX works with any biotinylated target captured on a glass surface. The Journal of Visualized Experiments (JoVE), a peer reviewed scientific video journal, recently featured ampliPHOX for its powerful pathogen detection abilities.

"ampliPHOX offers an incredible opportunity for a wide range of laboratories at a fraction of the cost," Kathy Rowlen, PhD, CEO and co-founder of InDevR, said. "With this technology, scientists can unleash the tremendous potential of low density microarrays for a myriad of applications; everything from pathogen detection with nucleic acids to disease state profiling with proteins."

In addition to saving money for lab analyses, the small reader and laptop will also save space, said Rowlen. ampliPHOX weighs just 3 pounds, is intended for easy transport and convenient storage in a lab and requires little on-site training.

"ampliPHOX is a product that will change the way technology works in labs around the world," said David Allen, PhD, associate vice president for technology transfer at CU. "CU technology contributed to this innovative product that will save money and time for countless scientists, which is especially helpful in our current economy."

Rowlen added that ampliPHOX is a success story for small business in America. "The intellectual property was licensed by InDevR from the University of Colorado; research and development was funded by the National Institute of Allergy and Infectious Disease; and I am especially pleased that the State of Colorado believed enough in InDevR to provide a small, but extremely helpful commercialization grant through the forward thinking BioScience Discovery Grant program. The result is a new technology on the market and new jobs in Colorado."

To make the ampliPHOX system even more affordable, InDevR currently offers free ampliPHOX instruments to customers who purchase 10 reagent kits. The limited-time offer is available on its website, http://www.indevr.com.


'/>"/>
Contact: Rhonda Spencer
spencer@indevr.com
303-402-9100
University of Colorado at Boulder
Source:Eurekalert

Related medicine news :

1. InDevR awarded $3 million grant from NIH for influenza-related research
2. State Sen. Jeff Klein launches Einsteins new lab
3. IPAL-EM launches to improve palliative care in emergency medicine
4. Harvard Medical School launches major initiative to address crisis in drug development
5. TGen-Virginia G. Piper Cancer Center launches clinical trial for drug to treat lung cancer
6. Autism Speaks launches blood draw tool kit -- practical guidance for parents and providers
7. UT Southwestern launches hand transplant program
8. 23andMe launches myeloproliferative neoplasms research initiative
9. International conference launches revolutionary South Asia autism network
10. DNDi launches new drug development program to address treatment needs of children with HIV/AIDS
11. UNH launches joint Sustainable Agro-Ecosystems Lab with Chinese Academy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... "The World Market for Companion Diagnostic Tests" report to ... World Market for Companion Diagnostics The World ... diagnostic and personalized medicine diagnostics. Market analysis in the report ... Diagnostics Test Market (In Vitro Diagnostic Kits) by Region (N. ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
Breaking Medicine Technology: